Large population studies have shown that unexplained B12 levels above 813 pg/mL are associated with an increased risk of cancer diagnosis within one year, though the absolute risk for any individual is still relatively low
Human clinical trial data is extremely limited
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
Vegans and Vegetarians : Since B12 is primarily found in animal products, those following a plant-based diet are often at risk of deficiency
The longest animal safety studies extended to 6 weeks of repeated dosing
